

PHARMACEUTICAL 2023

Cyteir Therapeutics Inc. Rank 37 of 446









RealRate

PHARMACEUTICAL 2023





The relative strengths and weaknesses of Cyteir Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cyteir Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 86% points. The greatest weakness of Cyteir Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 257%, being 214% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	149,209
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,315
Liabilities, Non-Current	1,631
Other Assets	2,324
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	2,109
Other Revenues	0
Property and Equipment	1,699
Research and Development	34,624
Selling, General and Administrative Expense	13,546

Output Variable	Value in 1000 USD
Assets	153,232
Liabilities	6,946
Expenses	48,170
Revenues	0
Stockholders Equity	146,286
Net Income	-46,061
Comprehensive Net Income	-46,061
Economic Capital Ratio	257%

